company background image
BEAM

Beam Therapeutics NasdaqGS:BEAM Stock Report

Last Price

US$42.51

Market Cap

US$2.9b

7D

18.8%

1Y

-54.7%

Updated

26 Jun, 2022

Data

Company Financials +
BEAM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BEAM Stock Overview

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.

Beam Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Beam Therapeutics
Historical stock prices
Current Share PriceUS$42.51
52 Week HighUS$138.52
52 Week LowUS$27.77
Beta1.6
1 Month Change30.56%
3 Month Change-26.75%
1 Year Change-54.70%
3 Year Changen/a
5 Year Changen/a
Change since IPO126.72%

Recent News & Updates

Shareholder Returns

BEAMUS BiotechsUS Market
7D18.8%10.3%6.6%
1Y-54.7%-24.3%-18.4%

Return vs Industry: BEAM underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: BEAM underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is BEAM's price volatile compared to industry and market?
BEAM volatility
BEAM Average Weekly Movement14.5%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: BEAM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BEAM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017394John Evanshttps://www.beamtx.com

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Beam Therapeutics Fundamentals Summary

How do Beam Therapeutics's earnings and revenue compare to its market cap?
BEAM fundamental statistics
Market CapUS$2.92b
Earnings (TTM)-US$238.29m
Revenue (TTM)US$60.27m

48.5x

P/S Ratio

-12.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BEAM income statement (TTM)
RevenueUS$60.27m
Cost of RevenueUS$99.30m
Gross Profit-US$39.03m
Other ExpensesUS$199.26m
Earnings-US$238.29m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.47
Gross Margin-64.76%
Net Profit Margin-395.37%
Debt/Equity Ratio0%

How did BEAM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BEAM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BEAM?

Other financial metrics that can be useful for relative valuation.

BEAM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue30.7x
Enterprise Value/EBITDA-17.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BEAM's PS Ratio compare to its peers?

BEAM PS Ratio vs Peers
The above table shows the PS ratio for BEAM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average143.8x

Price-To-Sales vs Peers: BEAM is good value based on its Price-To-Sales Ratio (48.5x) compared to the peer average (143.8x).


Price to Earnings Ratio vs Industry

How does BEAM's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: BEAM is expensive based on its Price-To-Sales Ratio (48.5x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is BEAM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BEAM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio48.5x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: BEAM is expensive based on its Price-To-Sales Ratio (48.5x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).


Share Price vs Fair Value

What is the Fair Price of BEAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BEAM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BEAM's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BEAM's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Beam Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BEAM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BEAM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BEAM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BEAM's revenue (18.2% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: BEAM's revenue (18.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BEAM is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Beam Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BEAM is currently unprofitable.

Growing Profit Margin: BEAM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BEAM is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.

Accelerating Growth: Unable to compare BEAM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BEAM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BEAM has a negative Return on Equity (-28.74%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Beam Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BEAM's short term assets ($1.2B) exceed its short term liabilities ($218.8M).

Long Term Liabilities: BEAM's short term assets ($1.2B) exceed its long term liabilities ($405.5M).


Debt to Equity History and Analysis

Debt Level: BEAM is debt free.

Reducing Debt: BEAM has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BEAM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BEAM is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 7.5% per year.


Discover healthy companies

Dividend

What is Beam Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BEAM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BEAM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BEAM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BEAM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BEAM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

John Evans (43 yo)

5.17yrs

Tenure

US$13,911,975

Compensation

Mr. John M. Evans is a Director at Prime Medicine, Inc. He serves as Chief Executive Officer and Director at Beam Therapeutics Inc. since January 2018 and served as its President since January 2018 until J...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD13.91M) is above average for companies of similar size in the US market ($USD6.88M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BEAM's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: BEAM's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BEAM insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.8%.


Top Shareholders

Company Information

Beam Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Beam Therapeutics Inc.
  • Ticker: BEAM
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.921b
  • Shares outstanding: 68.72m
  • Website: https://www.beamtx.com

Number of Employees


Location

  • Beam Therapeutics Inc.
  • 238 Main Street
  • 9th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.